 "pharma, medicines, drugs")
Shares of Jubilant Life Sciences surged 5.5 per cent to hit a 52-week high of Rs 909.75 on the BSE on Tuesday, a day after the company said it has launched the generic version of antiviral drug remdesivir in India for the treatment of Covid-19 patients.
The stock, however, erased its morning gains later and slipped into the negative territory. At 12:05 AM, the stock was quoting 2 per cent lower at Rs 845 on the BSE. It hit a low of Rs 840.45 against Monday's close of Rs 862.30.
In comparison, the S&P BSE Sensex was trading 547 points or nearly
